Helix BioMedix, Inc., founded in Bothell, United States, is a biopharmaceutical company specializing in peptide discovery and the development of treatments for rare dermatological diseases, such as xeroderma pigmentosum. The company's core mission is to address unmet medical needs in the rare skin disease market while also serving agricultural and industrial markets in the U.S. Helix BioMedix offers a vast library of proprietary peptides designed to leverage diverse structures and functions for therapeutic applications.
Notable figures associated with Helix BioMedix include its team of dedicated scientists who drive innovation in peptide research. The company has achieved significant milestones in drug development, contributing to advancements in the treatment of rare dermatological conditions. By focusing on novel drug development, Helix BioMedix has made a meaningful impact on both patient care and shareholder value, positioning itself as a key player in the biopharmaceutical industry.
